Catalyst Pharmaceutical Partners, a pharmaceutical company developing prescription drugs to treat addiction, set the terms for its IPO on Wednesday. The Florida-based company plans to offer 3 million shares at a range of $11-$13. The deal has a proposed market cap of $171 million. First Albany Capital and Stifel Nicolaus are set to manage the deal. Timing has yet to be announced.
